Clinical characteristics and treatment of 69 patients with extranodal natural killer T‑cell lymphoma

Guo,Yuyan; Li,Enxiao; Song,Liping; Wu,Yinying

doi:10.3892/mco.2016.1067

Clinical characteristics and treatment of 69 patients with extranodal natural killer T‑cell lymphoma

Authors:
- Yuyan Guo
- Enxiao Li
- Liping Song
- Yinying Wu
View Affiliations

Affiliations: Department of Radiotherapy Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaan'xi 710061, P.R. China, Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaan'xi 710061, P.R. China
Published online on: October 27, 2016 https://doi.org/10.3892/mco.2016.1067
Pages: 750-756
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was conducted to retrospectively analyze the clinical characteristics and survival of patients with extranodal natural killer‑T cell lymphoma (ENKL) and compare different treatment regimens. The univariate analysis demonstrated that survival was worse for patients with extranasal primary tumors, Eastern Cooperative Oncology Group performance status (ECOG PS) scores of ≥2, International Prognostic Index (IPI) scores of 3‑5, Ann Arbor stage III and IV disease, B symptoms, lymph node involvement and absence of radiotherapy. The Cox analysis demonstrated that ECOG PS score, stage, IPI, presence of B symptoms and radiotherapy were independent prognostic factors for overall survival (OS). The effect of diverse therapies on survival was then analyzed, and it was found that the 5‑year survival rate of patients receiving chemoradiotherapy differed significantly from that of patients who received chemotherapy alone [hazard ratio (HR)=0.347, P=0.0203], but did not differ significantly from the survival of patients treated with radiotherapy alone (HR=1.534, P=0.6371). A subgroup analysis revealed a difference between the radiotherapy and non‑radiotherapy groups for patients with extranasal‑type stage III/IV disease. It was concluded that ECOG score, stage, IPI, presence of B symptoms and radiotherapy were independent prognostic factors for OS in patients with ENKL. The addition of radiotherapy achieved better outcomes compared with chemotherapy alone, but no difference was observed between chemoradiotherapy and radiotherapy. Patients with advanced‑stage disease may also benefit from radiotherapy.

View Figures

View References

1	William BM and Armitage JO: International analysis of the frequency and outcomes of NK/T-cell lymphomas. Best Pract Res Clin Haematol. 26:23–32. 2013. View Article : Google Scholar : PubMed/NCBI
2	Zhang J, Wang WD, Geng QR, Wang L, Chen XQ, Liu CC and Lv Y: Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma. PloS One. 9:e946372014. View Article : Google Scholar : PubMed/NCBI
3	Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C, et al: Distribution of lymphoid neoplasms in China: Analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 138:429–434. 2012. View Article : Google Scholar : PubMed/NCBI
4	Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, et al: Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol. 24:612–618. 2006. View Article : Google Scholar : PubMed/NCBI
5	Jo JC, Yoon DH, Kim S, Lee BJ, Jang YJ, Park CS, Huh J, Lee SW, Ryu JS and Suh C: Clinical features and prognostic model for extranasal NK/T-cell lymphoma. Eur J Haematol. 89:103–110. 2012. View Article : Google Scholar : PubMed/NCBI
6	Li X, Liao WH, Zhou JH, Liu BA, Wen JF and Hu ZL: NK/T cell lymphoma involving mediastinum: Report of a case and review of literature. Int J Clin Exp Pathol. 7:6399–6402. 2014.PubMed/NCBI
7	Wang ZY, Liu QF, Wang H, Jin J, Wang WH, Wang SL, Song YW, Liu YP, Fang H, Ren H, et al: Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 120:2003–2010. 2012. View Article : Google Scholar : PubMed/NCBI
8	Chauchet A, Michallet AS, Berger F, Bedgedjian I, Deconinck E, Sebban C, Antal D, Orfeuvre H, Corront B, Petrella T, et al: Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. J Hematol Oncol. 5:272012. View Article : Google Scholar : PubMed/NCBI
9	Ma HH, Qian LT, Pan HF, Yang L, Zhang HY, Wang ZH, Ma J, Zhao YF, Gao J and Wu AD: Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma. Med Oncol. 27:798–806. 2010. View Article : Google Scholar : PubMed/NCBI
10	Zhang B, Zhu F, Liu X, Zhao J, Li M, Li Y, Huang J, Zou L and Chang Q: Radiotherapy combined with chemotherapy versus radiotherapy alone for early stage nasal natural killer/T-cell lymphoma: A meta-analysis. J Chemother. 28:65–71. 2016. View Article : Google Scholar : PubMed/NCBI
11	National Comprehensive Cancer Network, . NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas, Version 2. 2015.https://www.nccn.org/about/nhl.pdfAccessed July 13, 2015.
12	Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW: WHO classification of tumours of haematopoietic and lymphoid tissues. 2. 4th. World Health Organization; 2008
13	Kim SJ, Hong M, Do IG, Lee SH, Ryu KJ, Yoo HY, Hong JY, Ko YH and Kim WS: Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: Implications for a potential new prognostic indicator. Haematologica. 100:e106–e109. 2015. View Article : Google Scholar : PubMed/NCBI
14	Li YX, Wang H, Jin J, Wang WH, Liu QF, Song YW, Wang ZY, Qi SN, Wang SL, Liu YP, et al: Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 82:1809–1815. 2012. View Article : Google Scholar : PubMed/NCBI
15	Li YX, Liu QF, Wang WH, Jin J, Song YW, Wang SL, Liu YP, Liu XF, Zhou LQ and Yu ZH: Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy. Cancer. 117:5203–5211. 2011. View Article : Google Scholar : PubMed/NCBI
16	Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO and Liang R: International Peripheral T-Cell Lymphoma Project: Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 113:3931–3937. 2009. View Article : Google Scholar : PubMed/NCBI
17	Obama K: Concomitant use of radiotherapy and two topoisomerase inhibitors to treat adult T-cell leukemia with a radiotherapy-resistant bulky disease: A case series. Am J Blood Res. 4:106–109. 2014.PubMed/NCBI
18	Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY and Chim CS: SMILE for natural killer/T-cell lymphoma: Analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 120:2973–2980. 2012. View Article : Google Scholar : PubMed/NCBI
19	Lim YL, Pack HS, Park JE, Oh JR and Kong JH: Extranodal natural killer/T-cell lymphoma of the tenosynovium of the hand. Korean J Intern Med. 30:122–124. 2015. View Article : Google Scholar : PubMed/NCBI
20	Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, et al: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group study. J Clin Oncol. 29:4410–4416. 2011. View Article : Google Scholar : PubMed/NCBI
21	LaPorte J, Morris L and Koepke J: Long complete remission achieved with the combination therapy of Cisplatin and gemcitabine in a patient with aggressive natural killer cell leukemia. Case Rep Hematol. 2015:7156152015.PubMed/NCBI